XEN-D0501 / Pila Pharma - LARVOL DELTA

Epidemiological and mechanistic links between PM2.5 exposure and type 2 diabetes: focus on the TRPV1 receptor. (PubMed, Front Endocrinol (Lausanne)) - "Currently, XEN-D0501, a TRPV1 antagonist, is undergoing clinical trials to assess its efficacy in regulating blood glucose and mitigating T2D-related inflammatory complications...Targeted policies to reduce air pollution, together with intensified research into biological susceptibility and prevention strategies, are essential. Addressing PM2.5 as a modifiable determinant of T2D represents a timely and actionable priority in environmental health."

Journal • Review • Diabetes • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • TRPV1

A Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With Diabetes (clinicaltrials.gov) - P2 | N=54 | Completed | Sponsor: Pila Pharma

New P2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus